Novel GLP-1-based medications for type 2 diabetes and obesity
And Ill never forget, I was at a meeting at a restaurant and I was like, Excuse me. And Im picking up the phone and Im seeing the images come through from my sister-in-law, and its giant masses in my brothers liver
Rising Awareness and Access Issues Are Shaping Demand 47% of GLP-1 users are aware of the FDA's new policy shift that has restricted the availability of compounded semaglutide on the market, and 17% say it's been harder to get their medication because of it
doi: 10.1038/nn1908 195 TranP
348 Similarly, in human chondrocytes stimulated by TNF, GLP-1 analogs (such as liraglutide) showed an anti-catabolic effect, reducing the mRNA expression of MMP-3, MMP-13, and ADAMTS5
Sources: Davis SR, Castelo-Branco C, Chedraui P, et al